AUTHORS
Hannah Goulart, MD, Hagop Kantarjian, MD2, Nitin Jain, MD3, Farhad Ravandi, MD4, William G. Wierda, MD, PhD5, Gautam Borthakur, MD6, Tapan Kadia I, MD7, Maro Ohanian, DO8, Alex Bataller, MD, PhD9, Prithviraj Bose, MD10, Jan A. Burger, MD, PhD11, Kelly Sharon Chien, MD12, Fadi G. Haddad, MD13, Steven Kornblau, MD14, Naval Daver, MD15, Naveen Pemmaraju, MD16, Yesid Alvarado Valero, MD17, Courtney DiNardo, MD, MSCE18, Alessandra Ferrajoli III, MD19, Guillermo Montalban-Bravo, MD20, Musa Yilmaz, MD21, Michael Andreeff, MD, PhD22, Abhishek Maiti, MBBS23, Lucia Masarova, MD24, Koichi Takahashi, MD,PhD25, Christina Simon26, Rebecca Garris27, Guillermo Garcia-Manero, MD28, Nicholas Short, MD29, Elias Jabbour, MD30
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
27 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
28 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
29 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
30 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
Adults with relapsed and/or refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) have historically poor outcomes. Both inotuzumab ozogamicin (InO) and blinatumomab (blina) lead to high remission rates in R/R B-ALL, however, as single agents, the durability of response is limited. We developed a lower intensity regimen combining mini-CVD with InO and blina, initially administered sequentially and subsequently in a dose-dense fashion to facilitate earlier measurable residual disease (MRD) eradication. Here, we report the mature 3-year follow-up results from a phase 2 trial evaluating dose-dense mini-CVD in combination with InO and blina in adult patients (pts) with R/R B-ALL.
Methods
Pts>18 years old with R/R Philadelphia (Ph) positive (+) or Ph-negative (-) B-cell ALL were eligible to enroll in this trial. Pts received mini-hyper-CVD in combination with InO and blina in a dose-dense fashion: cycles 1, 3, 5 consisted of mini-hyper-CVD (cyclophosphamide 150 mg/m2 D1-3, vincristine 2mg D4, dexamethasone 20 mg D1-4, InO 0.6 mg/m2 D2 and 0.3 mg/m2 D8 [of C1], InO 0.3 mg/m2 D2 and 0.3 mg/m2 D8 [of C3], blina 9ug D4-5 and 28 ug D6-21 [of C1] and blina 28 ug D4-21 [of C3 and C5); cycles 2, 4, 6 consisted of mini-MTX and ara-C (MTX 250 mg/m2 D1, cytarabine 500 mg/m2 q12 hours D2-3, InO 0.3 mg/m2 D2 and 0.3 mg/m2 D8 [of C2 and C4], blina 28 mg D4-21), with Peg-G-CSF administered after each course. Pts received 12 IT chemotherapy administrations and rituximab if CD20 positive. All pts received ursodiol. Pts with Ph+ ALL received a concomitant BCR::ABL1 tyrosine kinase inhibitor.
Results
From September 2021-May 2026, 30 pts were enrolled with a median age of 39 years (range, 19-62); 4 pts (13)% >60 years and 17 pts (57%) male. Three pts (10%) had Ph+ ALL; the remaining (90%) had Ph- ALL, of which 9 (33%) had Ph-like disease. Three pts (10%) had adverse risk cytogenetics including 1 with KTMT2Ar. Six pts (20%) had a mutation in TP53. Twenty-six pts (87%) were in salvage 1, of which 7 (27%) had primary refractory disease and 5 (19%) pts had a duration of prior remission of <12 months. Three pts (10%) had previously undergone allogeneic stem cell transplantation (SCT) and 10 pts (33%) had previously received blina. No pt had previously received InO.
The overall response rate was 93% (28/30), with all pts achieving morphologic bone marrow remissions; 2 pts with ongoing extramedullary/CNS disease. Twenty-five of the evaluable pts (96%) achieved MRD-negativity by flow cytometry (FC) overall, with 20 (77%) achieving after 1 cycle. Twenty-one pts (84%) achieved MRD-negativity by next generation sequencing (NGS) by last follow-up, with 8 (38%) achieving after 1 cycle.
The median follow-up time is 36 months. Five pts (17%) proceeded to SCT consolidation, of which 3 pts (60%) relapsed (1 died); 2 pts (40%) are alive in CR after SCT. Eleven (37%) proceeded to CAR T consolidation (2 with obe-cel, 9 with brexu-cel; 9 [82%) were in salvage 1, 2 [18%] were in salvage 2); 9 of these pts (82%) are alive in remission; only 2 have relapsed (of which 1 died). At the time of CAR T infusion, 7/10 pts (70%) were NGS MRD-negative. Of the 3 pts with NGS-MRD positivity pre-CAR T, 2 became MRD-negative and 1 is below LOD post CAR T at last follow-up. Of the 2 pts who relapsed post CAR T, 1 did not have available NGS MRD, and one had persistent below LOD NGS MRD post CAR.
Of the remaining 14 pts, 6 (43%) are receiving ongoing consolidation/maintenance while in remission, 3 (21%) relapsed (2 died), and 2 (14%) died in CR (sepsis and klebsiella pneumonia).
Neither the median event-free survival (EFS) nor overall survival (OS) have been reached. The 3-year EFS and OS rates are 69% and 79%, respectively. These data are favorable compared to sequential mini-CVD InO Blina, where the 3-year EFS and OS rates were 32% (p=0.0067) and 40% (p=0.0016), respectively. The 3-year EFS and OS rates in pts who received CAR T consolidation were 82% and 89%, respectively, 80% and 100% in pts who received SCT consolidation and 51% and 57% in those undergoing maintenance therapy, respectively (p=0.19).
Conclusion
For adults with R/R B-cell ALL, dose-dense mini-CVD in combination with InO and blina leads to swift and deep responses, inducing NGS MRD negativity most pts. Proceeding to CAR T cell therapy in a minimal disease setting translates to promising survival at 3 years. This strategy is being evaluated in the frontline setting.
DISCLOSURES
Hannah Goulart, MD: No relevant conflicts of interest to declare.